Bernstein Maintains Outperform on Eli Lilly, Raises Price Target to $1385

Benzinga Newsdesk www.benzinga.com Positive 88.6%

Neg 0% Neu 0% Pos 88.6%

Bernstein analyst Courtney Breen maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $1300 to $1385.